New classification for identifying HR myeloma based on cytogenetic abnormalities
New classification for identifying HR myeloma based on cytogenetic abnormalities
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Multiple myeloma in a resource constrained setting